Balloon-Expandable Versus Self-Expanding Transcatheter Aortic Valve Replacement

Author:

Van Belle Eric1,Vincent Flavien1,Labreuche Julien2,Auffret Vincent3,Debry Nicolas1,Lefèvre Thierry4,Eltchaninoff Helene5,Manigold Thibaut6,Gilard Martine7,Verhoye Jean-Phillipe3,Himbert Dominique8,Koning Rene9,Collet Jean-Phillipe10,Leprince Pascal10,Teiger Emmanuel11,Duhamel Alain2,Cosenza Alessandro1,Schurtz Guillaume1,Porouchani Sina1,Lattuca Benoit12,Robin Emmanuel1,Coisne Augustin1,Modine Thomas1,Richardson Marjorie1,Joly Patrick13,Rioufol Gilles14,Ghostine Said15,Bar Olivier16,Amabile Nicolas17,Champagnac Didier18,Ohlmann Patrick19,Meneveau Nicolas20,Lhermusier Thibaut21,Leroux Lionel22,Leclercq Florence23,Gandet Thomas23,Pinaud Frédéric24,Cuisset Thomas25,Motreff Pascal26,Souteyrand Géraud26,Iung Bernard8,Folliguet Thierry27,Commeau Philippe28,Cayla Guillaume12,Bayet Gilles29,Darremont Olivier30,Spaulding Christian31,Le Breton Hervé3,Delhaye Cédric1

Affiliation:

1. Département de Cardiologie, Institut Coeur Poumon, Inserm U1011, Institut Pasteur de Lille, EGID (E.V.B., F.V., N.D., A. Cosenza, G. Schurtz, S.P., E.R., A. Coisne, T. Modine, M.R., C.D.)

2. Department of Biostatistics, EA 2694-Santé Publique: épidémiologie et Qualité des Soins (J.L., A.D.)

3. CHU de Lille, Université de Lille, France. CHU Pontchaillou, Service de Cardiologie et Maladies Vasculaires, CIC-IT 804, Université de Rennes 1, Laboratoire de Traitement du Signal et de l’Image, Inserm U1099, Rennes, France (V.A., J.P.-V., H.L.B.).

4. Institut Cardiovasculaire Paris-Sud, Hôpital Privé Jacques-Cartier, Massy, France (T. Lefèvre).

5. CHU Rouen–Charles-Nicolle, Service de Cardiologie, Inserm U644, Rouen, France (H.E.).

6. CHU Guillaume et René Laennec, Institut du Thorax, Service de Cardiologie, Nantes, France (T. Manigold).

7. CHU La Cavale Blanche, Département de Cardiologie, Optimisation des Régulations Physiologiques, UFR Sciences et Techniques, Brest, France (M.G.).

8. AP–HP, Hôpital Bichat, Département de Cardiologie, Université Paris-Diderot, France (D.H., B.I.).

9. Clinique Saint-Hilaire, Service de Cardiologie, Rouen, France (R.K.).

10. AP–HP, CHU La Pitié-Salpêtrière, Service de Cardiologie, Paris, France (J.-P.C., P.L.).

11. Hôpital Henri-Mondor Assistance Publique Hôpitaux de Paris, Département de Cardiologie, Créteil, France (E.T.).

12. CHU Nîmes, Cardiologie, Université Montpellier, Nimes, France (B.L., G.C.).

13. Hopital Saint-Joseph, Fédération de Cardiologie, Marseille, France (P.J.).

14. CHU Louis Pradel, Division de Cardiologie, Centre d’Investigation Clinique de Lyon (CIC), Bron, France (G.R.).

15. Centre Marie Lannelongue, Département de Cardiologie, Le Plessis Robinson, France (S.G.).

16. Clinique Saint Gatien, Service de Cardiologie, Tours, France (O.B.).

17. Institut Mutualiste Montsouris, Département de Cardiologie, Paris, France (N.A.).

18. Clinique du Tonkin, Service de Cardiologie, Villeurbanne, France (D.C.).

19. CHU de Strasbourg, Nouvel Hôpital Civil, Département de Cardiologie, Université de Strasbourg, France (P.O.).

20. CHU Besançon, Cardiologie, Hopital Jean Minjoz, Besançon, France (N.M.).

21. CHU de Toulouse, Département de Cardiologie, Inserm U1048, Université de Toulouse 3, France (T. Lhermusier).

22. Hôpital Cardiologique du Haut-Lévêque, Département de Cardiologie Interventionnelle, Université de Bordeaux, Pessac, France (L.L.).

23. CHU Arnaud de Villeneuve, Service de Cardiologie, Montpellier, France (F.L., T.G.).

24. CHU d’Angers, Service de Chirurgie Cardiaque, CNRS UMR 6214, INSERM 1083, Université d’Angers, France (F.P.).

25. CHU La Timone Assistance Publique Hôpitaux de Marseille, Département de Cardiologie, Inserm UMR1062, INRA UMR 1260, Université d’Aix-Marseille, France (T.C.).

26. CHU Gabriel Montpied, Département de Cardiologie, ISIT, CaVITI, CNRS (UMR-6284), Université d’Auvergne, Clermont-Ferrand, France (P.M., G. Souteyrand).

27. CHU de Nancy, Service de Chirurgie Cardiovasculaire, Vandoeuvre-lès-Nancy, France (T.F.).

28. Polyclinique les Fleurs, Cardiologie, Ollioules, France (P.C.).

29. Hôpital Privé Clairval, Service de Cardiologie, Marseille, France (G.B.).

30. Clinique Saint Augustin, Service de Cardiologie, Bordeaux, France (O.D.).

31. Hôpital Européen Georges Pompidou, Paris, France (C.S.).

Abstract

Background: No randomized study powered to compare balloon expandable (BE) with self expanding (SE) transcatheter heart valves (THVs) on individual end points after transcatheter aortic valve replacement has been conducted to date. Methods: From January 2013 to December 2015, the FRANCE-TAVI nationwide registry (Registry of Aortic Valve Bioprostheses Established by Catheter) included 12 141 patients undergoing BE-THV (Edwards, n=8038) or SE-THV (Medtronic, n=4103) for treatment of native aortic stenosis. Long term mortality status was available in all patients (median 20 months; interquartile range, 14 to 30). Patients treated with BE-THV (n=3910) were successfully matched 1:1 with 3910 patients treated with SE-THV by using propensity score (25 clinical, anatomical, and procedural variables) and by date of the procedure (within 3 months). The first coprimary outcome was ≥ moderate occurrence of paravalvular regurgitation or in-hospital mortality, or both. The second coprimary outcome was 2-year all-cause mortality. Results: In propensity–matched analyses, the incidence of the first coprimary outcome was higher with SE-THV (19.8%) compared with BE-THV (11.9%; relative risk, 1.68 [95% CI, 1.46–1.91]; P <0.0001). Each component of the outcome was also higher in patients receiving SE-THV: ≥ moderate paravalvular regurgitation (15.5% versus 8.3%; relative risk, 1.90 [95% CI, 1.63–2.22]; P <0.0001) and in hospital mortality (5.6% versus 4.2%; relative risk, 1.34 [95% CI, 1.07–1.66]; P =0.01). During follow up, all cause mortality occurred in 899 patients treated with SE-THV (2-year mortality, 29.8%) and in 801 patients treated with BE-THV (2-year mortality, 26.6%; hazard ratio, 1.17 [95% CI, 1.06–1.29]; P =0.003). Similar results were found using inverse probability of treatment weighting using propensity score analysis. Conclusion: The present study suggests that use of SE-THV was associated with a higher risk of paravalvular regurgitation and higher in-hospital and 2-year mortality compared with use of BE-THV. These data strongly support the need for a randomized trial sufficiently powered to compare the latest generation of SE-THV and BE-THV. Clinical Trial Registration: https://www.clinicaltrials.gov . Unique identifier: NCT01777828.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3